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come may be accomplished. Since mortality and morbidity 
increase with time without treatment, STEMI protocols are 
applied, with different methods and techniques to shorten 
ischaemic time delays [3, 4]. This involves many steps in 
a chain of ambulances, pre-hospital triage and treatment 
strategies, dedicated cardiac emergency units, ancillary 
paramedic personnel and additional measures, including 
monitoring of care for optimal quality. Furthermore, there 
is a strong relation between volume and outcome and nowa-
days it is widely recognised that a highly trained experi-
enced team treating STEMI patients performs better [5, 6]. 
This can be measured by mortality and morbidity, but also 
by monitoring and comparing weaker endpoints as hospital 
stay, quality of life, preservation of left ventricular function, 
readmissions, the need for re-interventions, and many more 
[6]. A network-oriented approach with triage and diagnosis 
by paramedics in the ambulance will bypass non-PCI cen-
tres in favour of PCI capable centres, and may thus further 
reduce time delays [7, 8]. If timely PCI cannot be accom-
plished, fibrinolytic therapy should be considered but there 
still is a large debate on the time delay that is acceptable, 
before deciding for this option, or when a combination of 
the two reperfusion modalities should be preferred [9–11]. 
In daily practice in the Netherlands, practically all STEMI 
patients can be transported to a dedicated PCI catheterisa-
tion lab within 60 min after first medical contact (FMC), 
usually the time of the emergency call [8, 12]. In this issue 
of the journal, Verweij et al. try to compare data on time 
delays and timing of intervention in different hospital set-
tings in the Netherlands and their conclusion is that a lot 
of data are inconsistent and/or incomplete or even missing 
or incorrect [13]. Of note: a correct registration of data is a 
prerequisite for having a license to perform interventional 
cardiology in the Netherlands. This observation deserves a 
careful analysis. First there is a variation in definition in the 
Abstract STEMI time delays have been introduced as a 
performance indicator or marker of quality of care. As they 
are only one part of a very complex medical process, one 
should be aware of concomitant issues that may be over-
looked or even be more important with regard to clinical 
outcome of STEMI patients. In this overview we try to 
summarise the most important ones.
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Introduction
Maybe the most important step forward in cardiology 
care is the early treatment of acute ischaemia of the heart. 
By performing immediate angiography in patients with 
the clinical presentation of an acute coronary syndrome 
(ACS), and more specifically when there are signs of ST 
elevation on the 12-lead ECG (ST-segment-elevation myo-
cardial infarction: STEMI), subsequent percutaneous coro-
nary intervention (PCI) to restore blood flow in blocked 
coronary arteries will save lives [1–3]. By improving the 
logistics surrounding these procedures, better results in out-
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international guidelines and in the literature in general [14, 
15]. This, in part, stems from a more regional than interna-
tional perspective but still accounts for much confusion. For 
instance, there is no universal definition of FMC, as is illus-
trated in Fig. 1. Second, in the Netherlands we regretfully 
still do not have a uniformly organised national cardiology 
data registry, such as in the UK or Sweden (Swedeheart)
[16], or the National Cardiovascular Data Registry (NCDR) 
in the US. This, in our view, deserves the highest priority of 
all stakeholders involved but is a political issue outside the 
context of this article.
Definition of STEMI time intervals
The most commonly used parameters or indicators are the 
time from symptom onset till effective reperfusion (total 
ischaemic time) and the median door-to-balloon time 
(D2BT), the latter supposed to represent the in-hospital 
performance. Besides, D2BT is easily determined and it 
was quickly introduced as a measure of quality of care of 
STEMI patients. The mean D2BT in our first study group 
of primary PCI patients in the early 1990s was only 61 min, 
although this concerned patients who were also eligible for 
fibrinolytic therapy [2]. Other issues sometimes addressed 
are: call-to-balloon time (CTB), time from FMC, time from 
first ECG, time to the catheterisation lab, time to coronary 
angiography, door-1 to door-2 time (D1D2 time) in case 
of inter-hospital transfer, and so on. All have their strong 
and weak points and often have to be registered in hectic 
situations, and during off-duty hours. For a comprehensive 
overview of system delays in primary angioplasty field tri-
age, we refer to Fig. 1. Furthermore, different hospitals use 
different electronic health records, with different databases, 
or still have to operate without automated system files. The 
pre-hospital phase data, mostly from ambulances, are usu-
ally stored separately. This inevitably accounts for the lack 
of consistency of methods and data registration and makes 
comparison among and between hospitals and/or health 
care providers difficult. However, we need these data to 
improve our performance and ability to monitor all aspects 
of this complicated chain of medical care, and to find ways 
for improvement, not only of the PCI procedure itself, but 
also its surrounding logistics. Our suggestion would be to 
count system time delay from first ECG to the time of start 
of coronary angiography (CAG), both being easily obtain-
able and above all, automatically stored in current practice. 
As primary angioplasty is the preferred treatment in almost 
all candidates identified by pre-hospital triage or by direct 
presentation to hospitals, we should not use the term ‘door-
to-needle time’ anymore, as was used in previous studies 
and surveys that concerned mainly patients who received 
fibrinolytic therapy [17].
International comparisons have demonstrated signifi-
cant differences in infarct care organisation and outcomes 
between countries, and national surveys have proven to be 
useful in improving the system and quality of care in STEMI 
patients [16, 18]. In many countries a substantial number of 
STEMI patients are not receiving any reperfusion therapy 
at all or receive it outside the guideline-recommended time-
frames, and implementation of the best reperfusion therapy 
as recommended in the guidelines should be encouraged. 
This includes efforts at reducing D2BT for STEMI patients 
undergoing primary angioplasty, regardless of the clinical 
setting or health care region.
In general, guidelines and quality-of-care programs for 
patients with STEMI arbitrarily recommend a D2BT of less 
than 90 min. for primary PCI.
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Fig. 1 Various delays when treating patients with ST-Elevation Myo-
cardial Infarction (STEMI) with primary percutaneous coronary in-
tervention (PPCI). ‘Healthcare system delay’ is the total delay from 
emergency medical service (EMS) call to PPCI. ‘PCI-related delay’ is 
the extra delay that one may use to perform PPCI and achieve effec-
tive reperfusion. First Medical Contact (either EMS call, EMS arrival 
on scene, or arrival at hospital according to regional STEMI system of 
care, after reference 15)
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whether they have features of STEMI. However, the net 
clinical benefit of emergency CAG in comatose OHCA 
survivors can only be assessed in prospective randomised 
studies, but as mortality in these patients is extremely 
high, efforts to improve survival and neurological out-
come deserve the highest priority.
 ● By focusing too much on the reported criteria—espe-
cially using time relapsing after FMC as an indicator of 
performance—we may miss an important moment of 
contemplation. Is the diagnosis correct? Is there addi-
tional pathology, for instance neurological trauma, renal 
impairment or a bleeding disorder? Should a CT scan 
of the brain be performed first? Are the other supportive 
measures of vital functions sufficient? Should mechani-
cal complications be ruled out? Is cardiac surgery a bet-
ter option and should we ask the cardiothoracic surgeon’s 
opinion first? This is more difficult in sicker patients, and 
it may take longer to decide on the right therapy [15, 27].
 ● Following the abovementioned reasoning, it does not 
seem justified to correct for anticipated time delays or 
to try to estimate the total ischaemic time for making the 
decision to proceed or not proceed to an invasive proce-
dure. This may lead to an incorrect approach, especially 
in sicker patients and those with high-risk features for 
mortality. If time delay is very long or if there is uncer-
tainty about total ischaemic time it may even lead to the 
decision not to intervene at all. As this is usually the case 
in sicker patients, who might have benefited the most, 
this may be an unwanted side effect of using time delays 
as a performance indicator [28].
 ● Although it seems reasonable to focus on system delays, 
the detrimental effects in the first hours may be overes-
timated, and the phrase ‘every minute of delay counts’ 
should be brought into perspective. Careful calculation 
shows that each 30 min of delay is associated with a 
relative risk for 1-year mortality of 1.05–1.07 [3, 29–31] 
However, this, in our view, in general allows for trans-
portation of stable STEMI patients to an experienced 
interventional centre and to think about correctness of 
diagnosis and the best treatment option in individual 
cases, as was mentioned above. Opportunities for opti-
mal STEMI patient care may be missed and patients may 
undergo an inappropriate early intervention.
 ● The currently established pathways of transfer of STEMI 
patients in the Netherlands are not likely to be improved 
by emphasis on time delays alone, and the impact on out-
come can certainly not be investigated in a randomised 
comparison. The scope of cardiologists in STEMI treat-
ment mainly puts the focus on shortening the time to 
treatment after the patient has arrived at the hospital. 
However, a large proportion of STEMI-related death has 
occurred before arrival at the hospital.
Important issues
There are important issues that should be addressed in rela-
tion to interpretation of STEMI time delays but are usually 
not taken into consideration:
 ● Sicker patients and patients with high-risk features 
undergo more delay [19]. There may be large differences 
in baseline characteristics in the patients studied. Prog-
nostic factors including age, comorbidities, presence of 
diabetes, previous myocardial infarction or congestive 
heart failure, haemodynamic state on admission and 
infarct size are usually not reported but may result in dif-
ferences in outcome [18, 20]. Above all, if adjustment for 
these characteristics is applied, time delay does not seem 
to be a significant determinant of outcome anymore.
 ● Despite reductions in D2BT, there has been little change 
during the past few years in in-hospital mortality, sug-
gesting that additional factors play an important role [21].
 ● Outcome and time delays may be related to the presenta-
tion of STEMI patients during off-duty hours. Patients 
with acute myocardial infarction who present during 
off-hours have a higher mortality than those who present 
during regular hours and a recent meta-analysis suggests 
that this is not directly related to total ischaemic time 
delays [22, 23]. However, the average D2BT appeared 
to be longer in off-hours and this may be an expression 
of variations in quality of care (number and expertise of 
staff, and other structural and process attributes in sys-
tems of care).
 ● High versus low volume centres: volume and outcome 
may translate into different outcomes and sicker patients 
may be presented more often to large volume centres [5, 
6].
 ● Operator skills, mode of vascular access (femoral versus 
radial route), procedural time, availability of advanced 
technology and surgical stand-by may all play an impor-
tant role and are usually not included as a variable, when 
it comes to comparison of outcome [12].
 ● Despite the shortest time delay, patients with out-of-
hospital cardiac arrest (OHCA) have the highest mor-
tality [19]. We need more data on the growing number 
of OHCA patients who are candidates for primary PCI 
and because OHCA is usually related to cardiac arrhyth-
mias on the basis of cardiac ischaemia, dedicated cardiac 
resuscitation centres have been proposed with promising 
results [24, 25]. These ideally should be equipped with 
24/7 primary angioplasty facilities, include therapeutic 
hypothermia capability and a specialised intensive care 
unit, fulfilling requirements for optimal post-resuscita-
tion care [26].
 ● Currently a debate is going on whether all OHCA patients 
should be scheduled for immediate CAG, regardless of 
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Conclusion
Shorter time delays will not necessarily translate into bet-
ter outcome and this puts time delay as performance indica-
tor into another perspective [19]. Of course initiatives and 
programs to reduce time delays have been successful and 
are needed, but we definitely should not promote them to 
the ultimate goal. By putting the focus of STEMI care too 
much on the simple comparison of time delays suggests that 
good clinical care can be data driven and a comparison with 
cholesterol-lowering drugs comes to mind: a 10 % drop in 
LDL cholesterol does not necessarily mean a reduction of 
10 % in adverse outcome.
Clinicians are treating sick patients and should realise that 
they do not perform well by producing nice indicators and 
criteria for hospital registrations, but by presenting patients 
the best treatment options available, although in a timely 
fashion. Reduction of time delays remains crucial in the 
treatment of the STEMI patient, but this is only one part of 
a very complex chain of medical care. Hospital administra-
tions, health care providers and politicians should be aware 
of the limited value of STEMI time delays as a quality indi-
cator. Although they are very helpful in streamlining logistic 
processes, they should not be considered as a proxy for hos-
pital performance or as a surrogate marker of quality of care.
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